KR20130094342A - 인간 표피 성장 인자 수용체 유전자 내의 돌연변이를 탐지하기 위한 방법 및 조성물 - Google Patents
인간 표피 성장 인자 수용체 유전자 내의 돌연변이를 탐지하기 위한 방법 및 조성물 Download PDFInfo
- Publication number
- KR20130094342A KR20130094342A KR1020137015963A KR20137015963A KR20130094342A KR 20130094342 A KR20130094342 A KR 20130094342A KR 1020137015963 A KR1020137015963 A KR 1020137015963A KR 20137015963 A KR20137015963 A KR 20137015963A KR 20130094342 A KR20130094342 A KR 20130094342A
- Authority
- KR
- South Korea
- Prior art keywords
- seq
- oligonucleotide
- nos
- artificial sequence
- oligonucleotides
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 230000035772 mutation Effects 0.000 title claims abstract description 85
- 238000000034 method Methods 0.000 title claims abstract description 28
- 101000851181 Homo sapiens Epidermal growth factor receptor Proteins 0.000 title claims description 8
- 239000000203 mixture Substances 0.000 title description 5
- 108091034117 Oligonucleotide Proteins 0.000 claims description 179
- 102000001301 EGF receptor Human genes 0.000 claims description 53
- 108060006698 EGF receptor Proteins 0.000 claims description 53
- 150000007523 nucleic acids Chemical class 0.000 claims description 46
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 claims description 44
- 102000039446 nucleic acids Human genes 0.000 claims description 44
- 108020004707 nucleic acids Proteins 0.000 claims description 44
- 239000002773 nucleotide Substances 0.000 claims description 33
- 125000003729 nucleotide group Chemical group 0.000 claims description 33
- 230000003321 amplification Effects 0.000 claims description 27
- 238000003199 nucleic acid amplification method Methods 0.000 claims description 27
- 238000001514 detection method Methods 0.000 claims description 22
- 239000011541 reaction mixture Substances 0.000 claims description 17
- 239000005411 L01XE02 - Gefitinib Substances 0.000 claims description 8
- XGALLCVXEZPNRQ-UHFFFAOYSA-N gefitinib Chemical compound C=12C=C(OCCCN3CCOCC3)C(OC)=CC2=NC=NC=1NC1=CC=C(F)C(Cl)=C1 XGALLCVXEZPNRQ-UHFFFAOYSA-N 0.000 claims description 8
- 238000009396 hybridization Methods 0.000 claims description 8
- 108090000623 proteins and genes Proteins 0.000 claims description 8
- 125000003277 amino group Chemical group 0.000 claims description 7
- 229940121647 egfr inhibitor Drugs 0.000 claims description 6
- 239000005551 L01XE03 - Erlotinib Substances 0.000 claims description 5
- AAKJLRGGTJKAMG-UHFFFAOYSA-N erlotinib Chemical compound C=12C=C(OCCOC)C(OCCOC)=CC2=NC=NC=1NC1=CC=CC(C#C)=C1 AAKJLRGGTJKAMG-UHFFFAOYSA-N 0.000 claims description 5
- 229960002584 gefitinib Drugs 0.000 claims description 5
- 238000003753 real-time PCR Methods 0.000 claims description 5
- 229960001433 erlotinib Drugs 0.000 claims description 4
- 239000002777 nucleoside Substances 0.000 claims description 4
- -1 nucleoside triphosphate Chemical class 0.000 claims description 4
- 229960001972 panitumumab Drugs 0.000 claims description 4
- 239000001226 triphosphate Substances 0.000 claims description 4
- 235000011178 triphosphate Nutrition 0.000 claims description 4
- 239000000872 buffer Substances 0.000 claims description 3
- 229960005395 cetuximab Drugs 0.000 claims description 3
- 239000003053 toxin Substances 0.000 claims 3
- 231100000765 toxin Toxicity 0.000 claims 3
- 206010028980 Neoplasm Diseases 0.000 abstract description 13
- 101100118549 Homo sapiens EGFR gene Proteins 0.000 abstract description 10
- 201000011510 cancer Diseases 0.000 abstract description 8
- 239000003153 chemical reaction reagent Substances 0.000 abstract description 6
- 231100000350 mutagenesis Toxicity 0.000 abstract 1
- 108020004414 DNA Proteins 0.000 description 125
- 239000000523 sample Substances 0.000 description 89
- 108700028369 Alleles Proteins 0.000 description 49
- 238000006243 chemical reaction Methods 0.000 description 12
- 108700021358 erbB-1 Genes Proteins 0.000 description 12
- 101150039808 Egfr gene Proteins 0.000 description 11
- 230000004048 modification Effects 0.000 description 11
- 238000012986 modification Methods 0.000 description 11
- 238000007844 allele-specific PCR Methods 0.000 description 10
- 230000000295 complement effect Effects 0.000 description 10
- 230000008859 change Effects 0.000 description 7
- 108091033319 polynucleotide Proteins 0.000 description 7
- 102000040430 polynucleotide Human genes 0.000 description 7
- 239000002157 polynucleotide Substances 0.000 description 7
- 230000000692 anti-sense effect Effects 0.000 description 5
- 238000011282 treatment Methods 0.000 description 5
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 4
- 238000003556 assay Methods 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 150000001413 amino acids Chemical class 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 238000013461 design Methods 0.000 description 3
- 239000012530 fluid Substances 0.000 description 3
- 229940084651 iressa Drugs 0.000 description 3
- 230000035945 sensitivity Effects 0.000 description 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 2
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 2
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 2
- 235000001014 amino acid Nutrition 0.000 description 2
- 238000002512 chemotherapy Methods 0.000 description 2
- 239000002299 complementary DNA Substances 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 238000002372 labelling Methods 0.000 description 2
- 208000020816 lung neoplasm Diseases 0.000 description 2
- 238000011275 oncology therapy Methods 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- 230000011664 signaling Effects 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 230000008685 targeting Effects 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- WKKCYLSCLQVWFD-UHFFFAOYSA-N 1,2-dihydropyrimidin-4-amine Chemical compound N=C1NCNC=C1 WKKCYLSCLQVWFD-UHFFFAOYSA-N 0.000 description 1
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- 108091023037 Aptamer Proteins 0.000 description 1
- 101100123850 Caenorhabditis elegans her-1 gene Proteins 0.000 description 1
- 108091026890 Coding region Proteins 0.000 description 1
- 108020004705 Codon Proteins 0.000 description 1
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
- AHCYMLUZIRLXAA-SHYZEUOFSA-N Deoxyuridine 5'-triphosphate Chemical compound O1[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)C[C@@H]1N1C(=O)NC(=O)C=C1 AHCYMLUZIRLXAA-SHYZEUOFSA-N 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 206010064571 Gene mutation Diseases 0.000 description 1
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Natural products NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 102000009465 Growth Factor Receptors Human genes 0.000 description 1
- 108010009202 Growth Factor Receptors Proteins 0.000 description 1
- 241000282414 Homo sapiens Species 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 108091054455 MAP kinase family Proteins 0.000 description 1
- 102000043136 MAP kinase family Human genes 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 238000012408 PCR amplification Methods 0.000 description 1
- 102000038030 PI3Ks Human genes 0.000 description 1
- 108091007960 PI3Ks Proteins 0.000 description 1
- 108091008611 Protein Kinase B Proteins 0.000 description 1
- 101800001295 Putative ATP-dependent helicase Proteins 0.000 description 1
- 101800001006 Putative helicase Proteins 0.000 description 1
- 102100033810 RAC-alpha serine/threonine-protein kinase Human genes 0.000 description 1
- 229940124639 Selective inhibitor Drugs 0.000 description 1
- 102000006943 Uracil-DNA Glycosidase Human genes 0.000 description 1
- 108010072685 Uracil-DNA Glycosidase Proteins 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 208000009956 adenocarcinoma Diseases 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 125000003295 alanine group Chemical group N[C@@H](C)C(=O)* 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000009949 anti-apoptotic pathway Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- IQXIUTMSTALSFW-VJFOLWCZSA-N carboplatin paclitaxel Chemical compound [NH2-].[NH2-].[Pt+2].OC(=O)C1(C(O)=O)CCC1.O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 IQXIUTMSTALSFW-VJFOLWCZSA-N 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 238000007385 chemical modification Methods 0.000 description 1
- SUYVUBYJARFZHO-RRKCRQDMSA-N dATP Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@H]1C[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 SUYVUBYJARFZHO-RRKCRQDMSA-N 0.000 description 1
- SUYVUBYJARFZHO-UHFFFAOYSA-N dATP Natural products C1=NC=2C(N)=NC=NC=2N1C1CC(O)C(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 SUYVUBYJARFZHO-UHFFFAOYSA-N 0.000 description 1
- RGWHQCVHVJXOKC-SHYZEUOFSA-J dCTP(4-) Chemical compound O=C1N=C(N)C=CN1[C@@H]1O[C@H](COP([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O)[C@@H](O)C1 RGWHQCVHVJXOKC-SHYZEUOFSA-J 0.000 description 1
- HAAZLUGHYHWQIW-KVQBGUIXSA-N dGTP Chemical compound C1=NC=2C(=O)NC(N)=NC=2N1[C@H]1C[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 HAAZLUGHYHWQIW-KVQBGUIXSA-N 0.000 description 1
- 230000000994 depressogenic effect Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 238000002405 diagnostic procedure Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000006862 enzymatic digestion Effects 0.000 description 1
- 229940082789 erbitux Drugs 0.000 description 1
- 238000001506 fluorescence spectroscopy Methods 0.000 description 1
- 238000001502 gel electrophoresis Methods 0.000 description 1
- 125000003630 glycyl group Chemical group [H]N([H])C([H])([H])C(*)=O 0.000 description 1
- 102000045108 human EGFR Human genes 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 230000001926 lymphatic effect Effects 0.000 description 1
- UEGPKNKPLBYCNK-UHFFFAOYSA-L magnesium acetate Chemical compound [Mg+2].CC([O-])=O.CC([O-])=O UEGPKNKPLBYCNK-UHFFFAOYSA-L 0.000 description 1
- 235000011285 magnesium acetate Nutrition 0.000 description 1
- 239000011654 magnesium acetate Substances 0.000 description 1
- 229940069446 magnesium acetate Drugs 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 102000054765 polymorphisms of proteins Human genes 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 239000001103 potassium chloride Substances 0.000 description 1
- 235000011164 potassium chloride Nutrition 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 150000003246 quinazolines Chemical class 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 229940120982 tarceva Drugs 0.000 description 1
- 210000001138 tear Anatomy 0.000 description 1
- 238000011191 terminal modification Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6844—Nucleic acid amplification reactions
- C12Q1/6851—Quantitative amplification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6813—Hybridisation assays
- C12Q1/6827—Hybridisation assays for detection of mutation or polymorphism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Immunology (AREA)
- Analytical Chemistry (AREA)
- Genetics & Genomics (AREA)
- Pathology (AREA)
- Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Hospice & Palliative Care (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201061426436P | 2010-12-22 | 2010-12-22 | |
| US61/426,436 | 2010-12-22 | ||
| PCT/EP2011/006399 WO2012084173A2 (en) | 2010-12-22 | 2011-12-17 | Methods and compositions for detecting mutation in the human epidermal growth factor receptor gene |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20130094342A true KR20130094342A (ko) | 2013-08-23 |
Family
ID=45478263
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020137015963A Ceased KR20130094342A (ko) | 2010-12-22 | 2011-12-17 | 인간 표피 성장 인자 수용체 유전자 내의 돌연변이를 탐지하기 위한 방법 및 조성물 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20120164641A1 (enExample) |
| EP (1) | EP2655659A2 (enExample) |
| JP (1) | JP2014500028A (enExample) |
| KR (1) | KR20130094342A (enExample) |
| CN (1) | CN103282515A (enExample) |
| AU (1) | AU2011348483A1 (enExample) |
| CA (1) | CA2822254A1 (enExample) |
| WO (1) | WO2012084173A2 (enExample) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2758546B1 (en) | 2011-09-23 | 2017-11-22 | Roche Diagnostics GmbH | Use of g-clamp for improved allele-specific pcr |
| US9382581B2 (en) | 2012-12-13 | 2016-07-05 | Roche Molecular Systems, Inc. | Primers with modified phosphate and base in allele-specific PCR |
| US9279146B2 (en) | 2012-12-21 | 2016-03-08 | Roche Molecular Systems, Inc. | Compounds and methods for the enrichment of mutated nucleic acid from a mixture |
| US9873908B2 (en) | 2013-11-27 | 2018-01-23 | Roche Molecular Systems, Inc. | Methods for the enrichment of mutated nucleic acid from a mixture |
| CN104087674B (zh) * | 2014-07-15 | 2016-02-10 | 江苏同科医药科技有限公司 | 一种人表皮生长因子受体突变基因检测试剂盒 |
| CN106795567B (zh) * | 2014-10-09 | 2021-07-30 | 豪夫迈·罗氏有限公司 | 在表皮生长因子受体激酶结构域中的突变 |
| CZ308881B6 (cs) | 2014-12-09 | 2021-08-04 | Univerzita Palackého v Olomouci | 6-aryl-9-glykosylpuriny a jejich použití |
| CN105177156B (zh) * | 2015-10-12 | 2018-04-10 | 苏州华益美生物科技有限公司 | 人egfr基因突变检测试剂盒及其应用 |
| CN108676848B (zh) * | 2018-05-31 | 2022-04-22 | 上海科医联创医学检验所有限公司 | 用于检测融合基因的混合基因、标准质粒、试剂盒及其制备方法 |
| CN111607593A (zh) * | 2019-02-26 | 2020-09-01 | 成都华青精准医疗科技有限公司 | 一种用于检测egfr基因突变的核苷酸序列组及其应用 |
| CN113355423B (zh) * | 2021-07-07 | 2022-06-07 | 安徽科技学院 | Egfr基因l858r突变检测的引物探针、试剂盒及其应用 |
| CN117106865B (zh) * | 2023-08-23 | 2024-05-10 | 北京医院 | 基于双扩增放大和双lna探针特异识别dna突变的高灵敏检测方法 |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5981725A (en) * | 1989-09-08 | 1999-11-09 | The Johns Hopkins Univiersity | Structural alterations of the EGF receptor gene in human tumors |
| US5981176A (en) | 1992-06-17 | 1999-11-09 | City Of Hope | Method of detecting and discriminating between nucleic acid sequences |
| EP0866071B1 (en) * | 1997-03-20 | 2004-10-20 | F. Hoffmann-La Roche Ag | Modified primers |
| AU2520799A (en) * | 1998-02-05 | 1999-08-23 | Bavarian Nordic Research Institute A/S | Quantification by inhibition of amplification |
| US6235480B1 (en) * | 1998-03-13 | 2001-05-22 | Promega Corporation | Detection of nucleic acid hybrids |
| JP2004508019A (ja) * | 2000-07-28 | 2004-03-18 | コンピュジェン インコーポレイテッド | トランスクリプトームの中に場所を占めるｒｎａ転写物及びスプライス変異体を検出するためのオリゴヌクレオチドライブラリー |
| EP2439285B1 (en) | 2004-03-31 | 2019-05-08 | The General Hospital Corporation | Method to determine responsiveness of cancer to epidermal growth factor receptor targeting treatments |
| EP2592155B2 (en) | 2004-06-04 | 2019-09-11 | Genentech, Inc. | EGFR mutations |
| KR20070106029A (ko) * | 2005-02-24 | 2007-10-31 | 암젠 인코포레이티드 | 상피세포 성장 인자 수용체 돌연변이 |
| GB2424886A (en) * | 2005-04-04 | 2006-10-11 | Dxs Ltd | Polynucleotide primers against epidermal growth factor receptor and method of detecting gene mutations |
| CN1710102A (zh) * | 2005-06-20 | 2005-12-21 | 上海市肺科医院 | 一种肿瘤相关基因突变的pcr检测方法及试剂系统 |
| US20070072211A1 (en) * | 2005-06-30 | 2007-03-29 | Roche Molecular Systems, Inc. | Asymmetric PCR coupled with post-PCR characterization for the identification of nucleic acids |
| CN101041850A (zh) * | 2006-03-20 | 2007-09-26 | 吕成伟 | 一种人类表皮生长因子受体（egfr）基因外显子20的t790m突变快速检测方法和试剂盒 |
| US8598333B2 (en) * | 2006-05-26 | 2013-12-03 | Alnylam Pharmaceuticals, Inc. | SiRNA silencing of genes expressed in cancer |
| EP2337865B1 (en) | 2008-10-20 | 2014-11-19 | Roche Diagnostics GmbH | Allele-specific amplification using a primer with a modified nucleotide |
| US20100143901A1 (en) | 2008-12-09 | 2010-06-10 | Roche Molecular Systems, Inc. | Nuclease-Free Real-Time Detection of Nucleic Acids |
-
2011
- 2011-12-13 US US13/324,705 patent/US20120164641A1/en not_active Abandoned
- 2011-12-17 AU AU2011348483A patent/AU2011348483A1/en not_active Abandoned
- 2011-12-17 EP EP11808168.6A patent/EP2655659A2/en not_active Withdrawn
- 2011-12-17 KR KR1020137015963A patent/KR20130094342A/ko not_active Ceased
- 2011-12-17 CN CN2011800611832A patent/CN103282515A/zh active Pending
- 2011-12-17 WO PCT/EP2011/006399 patent/WO2012084173A2/en not_active Ceased
- 2011-12-17 JP JP2013545098A patent/JP2014500028A/ja active Pending
- 2011-12-17 CA CA2822254A patent/CA2822254A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| AU2011348483A1 (en) | 2013-06-13 |
| WO2012084173A2 (en) | 2012-06-28 |
| CN103282515A (zh) | 2013-09-04 |
| JP2014500028A (ja) | 2014-01-09 |
| CA2822254A1 (en) | 2012-06-28 |
| WO2012084173A3 (en) | 2012-10-26 |
| EP2655659A2 (en) | 2013-10-30 |
| US20120164641A1 (en) | 2012-06-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR20130094342A (ko) | 인간 표피 성장 인자 수용체 유전자 내의 돌연변이를 탐지하기 위한 방법 및 조성물 | |
| JP6619332B2 (ja) | ヒトｅｚｈ２遺伝子中の変異を検出するための方法及び組成物 | |
| KR20080028857A (ko) | ＥｒｂＢ 수용체 약물에 대한 환자반응을 예측 및 모니터링하는 방법 | |
| EP2971075B1 (en) | Methods and compositions for detecting mutations in the human pi3kca (pik3ca) gene | |
| CN103930567B (zh) | 表皮生长因子受体激酶结构域中的新型复合突变 | |
| JP6205216B2 (ja) | 変異検出用プローブ、変異検出方法、薬効判定方法及び変異検出用キット | |
| CN104812916A (zh) | 表皮生长因子受体激酶结构域中的新型突变 | |
| CN106795567B (zh) | 在表皮生长因子受体激酶结构域中的突变 | |
| WO2012065705A1 (en) | Novel complex mutation in the epidermal growth factor receptor kinase domain |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A201 | Request for examination | ||
| PA0105 | International application |
Patent event date: 20130620 Patent event code: PA01051R01D Comment text: International Patent Application |
|
| PA0201 | Request for examination | ||
| PG1501 | Laying open of application | ||
| E902 | Notification of reason for refusal | ||
| PE0902 | Notice of grounds for rejection |
Comment text: Notification of reason for refusal Patent event date: 20140924 Patent event code: PE09021S01D |
|
| E601 | Decision to refuse application | ||
| PE0601 | Decision on rejection of patent |
Patent event date: 20150223 Comment text: Decision to Refuse Application Patent event code: PE06012S01D Patent event date: 20140924 Comment text: Notification of reason for refusal Patent event code: PE06011S01I |